Evaluation of pharmacokinetic interactions between long‐acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084

Documents similaires

• Generalizing the intention-to-treat effect of an active control against placebo from historical placebo-controlled trials to an active-controlled trial: A case study of the efficacy of daily oral TDF/FTC in the HPTN 084 study
  par: He, Qijia, et autres
  Publié: (2023)
• No observed bidirectional effect between tenofovir diphosphate concentrations and gender‐affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre‐exposure prophylaxis
  par: Nimish Patel, et autres
  Publié: (2024)
• Cluster headache‐like symptoms after initiation of tenofovir disoproxil fumarate and emtricitabine‐containing regimens for post‐ HIV exposure prophylaxis
  par: Alberto Foncillas, et autres
  Publié: (2024)
• Synthesis and characterization of tenofovir disoproxil fumarate loaded nanoparticles for HIV‐1 treatment
  par: Oluwafemi Samuel Obisesan, et autres
  Publié: (2024)
• Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes
  par: Huey‐Ling Chen, et autres
  Publié: (2024)